Ionis Pharmaceuticals, Inc. Common Stock IONS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:55:05.793Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:46:03.316379286Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:55:05.437286+00:00
Ionis Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 25.86 | 64.3% | 9.6% | |||
| 25Δ | 31.06 | 78.0% | 11.9% | 26.32 | 64.3% | 8.4% |
| 30Δ | 30.32 | 75.7% | 9.7% | 26.77 | 64.3% | 7.2% |
| 35Δ | 29.76 | 73.6% | 8.2% | 27.23 | 64.4% | 6.0% |
| 40Δ | 29.34 | 71.7% | 7.2% | 27.66 | 64.6% | 5.1% |
| 45Δ | 28.93 | 69.8% | 6.2% | 28.05 | 65.1% | 4.5% |
| 50Δ | 28.51 | 68.0% | 5.2% | 28.44 | 65.7% | 4.0% |
| 55Δ | 28.09 | 66.1% | 4.3% | 28.83 | 66.2% | 3.4% |
| 60Δ | 27.68 | 64.2% | 3.3% | 29.22 | 66.8% | 2.9% |
| 65Δ | 27.13 | 67.7% | 2.7% | 29.62 | 67.3% | 2.4% |
| 70Δ | 26.50 | 75.1% | 2.4% | 30.08 | 68.3% | 1.8% |
| 75Δ | 25.86 | 82.5% | 2.1% | 34.73 | 94.1% | 1.5% |
| 80Δ | 25.22 | 89.9% | 1.7% | 39.37 | 120.0% | 1.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.86
- IV
- 64.3%
- B/E move
- 9.6%
25Δ
- Pseudo strike
- 31.06
- IV
- 78.0%
- B/E move
- 11.9%
- Pseudo strike
- 26.32
- IV
- 64.3%
- B/E move
- 8.4%
30Δ
- Pseudo strike
- 30.32
- IV
- 75.7%
- B/E move
- 9.7%
- Pseudo strike
- 26.77
- IV
- 64.3%
- B/E move
- 7.2%
35Δ
- Pseudo strike
- 29.76
- IV
- 73.6%
- B/E move
- 8.2%
- Pseudo strike
- 27.23
- IV
- 64.4%
- B/E move
- 6.0%
40Δ
- Pseudo strike
- 29.34
- IV
- 71.7%
- B/E move
- 7.2%
- Pseudo strike
- 27.66
- IV
- 64.6%
- B/E move
- 5.1%
45Δ
- Pseudo strike
- 28.93
- IV
- 69.8%
- B/E move
- 6.2%
- Pseudo strike
- 28.05
- IV
- 65.1%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- 28.51
- IV
- 68.0%
- B/E move
- 5.2%
- Pseudo strike
- 28.44
- IV
- 65.7%
- B/E move
- 4.0%
55Δ
- Pseudo strike
- 28.09
- IV
- 66.1%
- B/E move
- 4.3%
- Pseudo strike
- 28.83
- IV
- 66.2%
- B/E move
- 3.4%
60Δ
- Pseudo strike
- 27.68
- IV
- 64.2%
- B/E move
- 3.3%
- Pseudo strike
- 29.22
- IV
- 66.8%
- B/E move
- 2.9%
65Δ
- Pseudo strike
- 27.13
- IV
- 67.7%
- B/E move
- 2.7%
- Pseudo strike
- 29.62
- IV
- 67.3%
- B/E move
- 2.4%
70Δ
- Pseudo strike
- 26.50
- IV
- 75.1%
- B/E move
- 2.4%
- Pseudo strike
- 30.08
- IV
- 68.3%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 25.86
- IV
- 82.5%
- B/E move
- 2.1%
- Pseudo strike
- 34.73
- IV
- 94.1%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 25.22
- IV
- 89.9%
- B/E move
- 1.7%
- Pseudo strike
- 39.37
- IV
- 120.0%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 49.49% | |
| 51.12% | |
| 50.63% | |
| 52.35% | |
| 50.69% | |
| 50.62% | |
| 50.41% | |
| 49.62% | |
| 50.53% | |
| 52.96% |
Biotechnology
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →IRD
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge…
More →IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious…
More →IVA
Description unavailable
More →IVVD
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious…
More →